Valuation: Simcere Pharmaceutical Group Limited

Market Cap 408.27Cr 3.2TCr 352.62Cr 331.77Cr 301.54Cr 567.15Cr 39TCr 575.46Cr 3.89TCr 1.53TCr 20TCr 1.53TCr 1.5TCr 65TCr P/E 2026 *
16.1x
P/E 2027 * 14x
Enterprise Value 389.58Cr 3.06TCr 336.48Cr 316.59Cr 287.73Cr 541.19Cr 37TCr 549.12Cr 3.71TCr 1.46TCr 19TCr 1.46TCr 1.43TCr 62TCr EV / Sales 2026 *
2.61x
EV / Sales 2027 * 2.35x
Free-Float
32.48%
Yield 2026 *
3.3%
Yield 2027 * 3.8%
30/07 Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2026 CI
09/07 Simcere Pharma's Acute Ischemic Stroke Included in National Essential Medicines List MT
15/06 Simcere Pharma Gets China Nod for Tumor Drug Trial MT
12/06 Simcere Pharmaceutical Group Limited Receives Clinical Trial Approval for Sim0689 Pd-1/Vegf Bispecific Antibody CI
12/06 Simcere Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2025, Payable on or Before July 13, 2026 CI
12/06 Simcere Pharmaceutical Group Limited Enters into A Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis CI
02/06 Simcere Pharma Wins Promotion Rights for PrimeGenX's Atopic Dermatitis Drug MT
01/06 Simcere Pharmaceutical Group Limited Enters into Exclusive Promotion Service Agreement with PrimeGenX Therapeutics Co., Ltd CI
21/05 Simcere Pharmaceutical Group Limited Proposes to Declare A Final Dividend for the Year Ended December 31, 2025 CI
06/05 Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0613 LRRC15 Antibody Drug Conjugate CI
06/05 Simcere pharmaceutical receives NMPA China clinical trial approval for SIM0613 RE
06/05 Simcere Pharmaceutical Receives Chinese Regulatory Approval to Begin Trials of Tumor Drug MT
04/05 Wuxi Biocity Biopharmaceutics Co., Ltd. announced that it has received funding from Simcere Pharmaceutical Group Limited, First Light Capital CI
1 day-2.41%
1 week-1.46%
Current month-1.46%
1 month-3.49%
3 months+8.86%
6 months-3.41%
Current year+1.67%
1 week 12.02
Extreme 12.02
12.58
1 month 11.63
Extreme 11.63
13.52
Current year 9.07
Extreme 9.07
14.28
1 year 9.07
Extreme 9.07
15.08
3 years 4.94
Extreme 4.94
15.08
5 years 4.94
Extreme 4.94
15.08
10 years 4.94
Extreme 4.94
15.08
Manager TitleAgeSince
Chief Executive Officer 54 25/03/2026
Director of Finance/CFO 55 19/11/2019
Chief Tech/Sci/R&D Officer 51 01/12/2023
Director TitleAgeSince
Chairman 63 08/10/2012
Director/Board Member 55 19/11/2019
Director/Board Member 46 01/11/2019
Date Insider Type Main position Quantity % Market Cap.
13/07/26 Other

Founder

-47,000 0.0018%
13/07/26 Other

Director

-47,000 0.0018%
10/07/26 Other

Founder

-53,000 0.0021%
Change 5-day change 1-year change 3-year change Capi.($)
-2.41%-1.46%-1.22%+91.65% 408.27Cr
+1.33%-2.16%+16.37%+67.42% 4.7TCr
+0.12%-4.02%+52.13%+123.20% 3.96TCr
-0.64%-2.80%-9.15%+15.01% 1.21TCr
-0.99%-7.26%+11.96%+70.49% 1.16TCr
+0.58%0.00%+30.65%+147.62% 911.43Cr
-0.39%-1.15%+19.93%+39.54% 746.99Cr
+0.80%+1.69%+45.73%-11.26% 718.48Cr
-2.54%-1.30%+13.81%+193.20% 678.89Cr
-3.28%-5.51%-32.65%+20.83% 574.96Cr
Average -0.74%-1.98%+14.76%+75.77% 1.51TCr
Weighted average by Cap. +0.07%-2.97%+23.37%+82.39%

Financials

2026 *2027 *
Net sales 149.46Cr 1.17TCr 129.09Cr 121.46Cr 110.39Cr 207.63Cr 14TCr 210.67Cr 1.42TCr 558.35Cr 7.16TCr 561.16Cr 548.98Cr 24TCr 168.83Cr 1.32TCr 145.82Cr 137.2Cr 124.69Cr 234.53Cr 16TCr 237.97Cr 1.61TCr 630.7Cr 8.09TCr 633.88Cr 620.12Cr 27TCr
Net income 25Cr 193.03Cr 21Cr 20Cr 18Cr 34Cr 2.36TCr 35Cr 234.58Cr 92Cr 1.18TCr 92Cr 90Cr 3.93TCr 29Cr 229.38Cr 25Cr 24Cr 22Cr 41Cr 2.8TCr 41Cr 278.74Cr 109.24Cr 1.4TCr 109.79Cr 107.41Cr 4.67TCr
Net Debt -19Cr -146.59Cr -16Cr -15Cr -14Cr -26Cr -1.79TCr -26Cr -178.14Cr -70Cr -895.54Cr -70Cr -69Cr -2.98TCr -12Cr -96Cr -11Cr -9.96Cr -9.05Cr -17Cr -1.17TCr -17Cr -116.84Cr -46Cr -587.39Cr -46Cr -45Cr -1.96TCr
Logo Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Ltd is a company engaged in research and development, production and sales of drugs. The Company's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The Company also produces various drugs, including Endostar used for oncology. The Company is also involved in providing promotion services for third-party drugs sold by medical institutions. The Company mainly conducts its businesses in the domestic market and overseas markets.
Employees
7,038
Date Price Change Volume
19/26/19 HK$12.17 -2.41% 49,67,000
18/26/18 HK$12.47 +0.81% 40,99,000
17/26/17 HK$12.37 +1.89% 62,06,126
14/26/14 HK$12.14 -0.25% 41,02,000
13/26/13 HK$12.17 -0.41% 54,98,406
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
10.46CNY
Average target price
15.33CNY
Spread / Average Target
+46.51%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2096 Stock